Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.74 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | GPR27 | Q9NS67 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416712 | 0.87 | CDK2 (0.74) | CDK2MEN1KMT2A | |
| SCHEMBL4419524 | 0.85 | CDK2 (1.00) | CDK2CDK1 | |
| SCHEMBL4414254 | 0.83 | CDK2 (0.77) | CDK2MEN1KMT2ACDK1 | |
| SCHEMBL4413597 | 0.82 | CDK2 (0.72) | CDK2CDK1 | |
| SCHEMBL6027265 | 0.81 | CDK2 (0.73) | CDK2MEN1KMT2AGAA | |
| SCHEMBL6695987 | 0.76 | CDK2 (0.59) | CDK2MEN1KMT2A | |
| SCHEMBL4411192 | 0.75 | CDK2 (0.61) | CDK2MEN1KMT2ACDK1 | |
| SCHEMBL4412149 | 0.73 | CDK2 (0.81) | CDK2CDK1 | |
| SCHEMBL4411104 | 0.69 | CDK2 (0.72) | CDK2MEN1KMT2AALDH1A1CDK1 | |
| SCHEMBL6027091 | 0.69 | CDK2 (0.54) | CDK2MEN1KMT2ACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689394-A4 | AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-03 | — | — | EP | disclosed |
| US-7109220-B2 | Amino substituted pyridinyl methanone compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-19 | — | — | US | disclosed |
| EP-1689394-A1 | AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051387-A1 | AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-09 | — | — | WO | disclosed |
| US-20050124610-A1 | Amino substituted pyridinyl methanone compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N. V. (BE) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124610-A1 | Amino substituted pyridinyl methanone compounds useful in treating kinase disorders | CDK6, CDK1, CDK3 | CDK2 4/4885PKM 153/4885FFAR4 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.